Vascular Closure Devices Market By Product Type (Mechanical Closure Devices {Clip-based devices, Suture-based devices}, Passive Closure Devices {Collagen-based devices, Gel-based devices}, Active Closure Devices {Balloon-assisted devices, Other active devices}), By Application (Cardiology, Radiology, Interventional Procedures, Peripheral Vascular Interventions, Others), By Material (Polymer-based closure devices, Suture-based closure devices, Metal-based closure devices, Collagen-based closure devices, Others), By End-User (Hospitals, Ambulatory Surgical Centers (ASCs), Specialty Clinics, Diagnostic Imaging Centers), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Industry Outlook

The Vascular Closure Devices market accounted for USD 1.46 Billion in 2024 and is expected to reach USD 3.1 Billion by 2035, growing at a CAGR of around 7.1% between 2025 and 2035. The vascular closure devices [VCD] market includes medical devices used to seal access sites in blood vessels that have been opened for minimally invasive procedures such as catheterization. It is believed that these devices will reduce various issues and cut the time required to achieve hemostasis more effectively than manual compression. The market has vigorous growth potential due to the growing prevalence of cardiovascular diseases, the development of interventional procedures, and focusing on patient safety and outcomes. Stakeholders continue to actively promote the usage of the devices in a more advanced and effective manner and participate in the market's growth.

Report Scope:

Market Dynamics

Increasing prevalence of cardiovascular diseases drives device demand.

The prevalence of cardiovascular disorders has significantly enhanced the market for vascular closure devices. The high incidence of obesity and diabetes and the tendency to live sedentary lives have elevated the risk of cardiovascular disease. Moreover, improvements in less invasive methods improve outcomes and adoption rates for these devices. It increases the demand for cardiovascular therapy, necessitating effective patient closure strategies. Regulatory approval and product innovation are important factors in market development. According to the CDC, approximately 0.6 million people died in the United States in 2020 as a result of heart disease, emphasizing the importance of high-quality medical equipment. Healthcare companies around the United States are looking for more efficient solutions, meaning that the market for vascular closure devices will certainly grow. As this development demonstrates, these devices provide significant relief for cardiovascular health conditions.

Rising healthcare expenditure supports advanced medical technology adoption.

The vascular closure devices (VCD) market is driven by increased global healthcare spending and enhanced technology adoption. Elevated rates of cardiovascular disorders and the constantly aging population contribute to the need for first-class vascular therapies. With the growth of minimally invasive surgery and treatments, the patient's outcome improves even further, and more practitioners and surgeons prefer VCDs over normal suturing techniques. The increased procedural use of catheter-based therapies, including angioplasty and stenting for treatment, requires effective closure solutions to avoid adverse events.

A favorable regulatory environment and increased appropriations for the development of healthcare solutions are other drivers of the market. Moreover, as ambulatory surgery facilities become more accessible, there is a greater demand for high-speed recovery options, which favors VCD. The vascular closure device market is expanding due to increased awareness of its use among medical workers and patients. Collaborations between manufacturers and healthcare companies to ensure that these technologies reach different parts of the market help accelerate the market’s advancement.

Alternative closure techniques can reduce demand for dedicated devices

Few issues have been identified as impeding the expansion of the vascular closure devices (VCDs) market. These gadgets are costly, making them difficult for healthcare facilities in developing countries to afford. These methods show that less expensive closure approaches can be used even when more effective alternatives exist, such as manual compression or suturing. VCD problems, including infection or bleeding, render the treatment ineffective. VCD complications, such as infection or bleeding, make the treatment ineffective. Optimum regulations and bureaucratic procedures toward the approval of new devices might reduce product diffusion and market growth. The growing focus on least-invasive interventions may make the providers look for other options that do not require such tools. Reimbursement policies impact the economic viability of VCDs in clinical settings.

Innovative product development can enhance features and safety profiles.

The global potential for the Vascular Closure Devices (VCD) market will be fueled by new product innovations that prioritize safety and features. That is why the demand for efficient VCDs is increasing in tandem with the trend toward developing healthcare systems based on less intrusive treatments for a variety of ailments, including cardiac and peripheral ones. Technological developments, such as expandable bioabsorbable materials, improved delivery systems, and sophisticated technology integration in IDT systems can improve patient outcomes and reduce problems. Furthermore, the rising incidence of cardiovascular diseases and an expanding elderly population raise the pool of patients requiring such solutions. Governments continue to encourage research and development through regulation and money, which aids market evolution. Targeted clinician education can help enhance device use and lower injury rates. Overall, the VCD market will expand in response to technological advances and shifts in healthcare demand.

Strategic partnerships drive innovation and expand market reach effectively

The Vascular Closure Devices (VCD) market has significant opportunities through partnerships that contribute to the generation of new concepts and geographical reach. If medical device companies, healthcare professionals, and technology companies get together, they could improve the design and functionality of VCDs using new and smart materials. This synergy enables the development of products that enhance internal patients’ results, besides increasing procedural efficiency. Furthermore, partnerships facilitate entry into new markets by acquiring locals who understand the regulatory framework required to operate in a new market, such as expanding healthcare markets. To capitalize on this trend, strategic partnerships and teamwork are required to build innovative solutions. Furthermore, regional cooperative marketing will broaden the reach of current brands and increase the items' appeal to healthcare practitioners. Combined resources and knowledge result in speedier research and development, leading to faster commercial advantage in an environment where vascular medicines are changing.

Industry Experts Opinion

"Despite the evolution of vascular closure technology, manual compression remains the gold standard. It provides reliable hemostasis, although VCDs can enhance patient comfort and speed up recovery in the right settings"​

• Dr. B. R. Das, Vascular Surgeon, Radcliffe Cardiology.

."While VCDs can significantly reduce time to ambulation and improve patient satisfaction, they also introduce new potential complications that must be managed effectively"​

• Dr. Alan G. T. Becker, Interventional Cardiologist, Radcliffe Cardiology.

Segment Analysis

Based on the product type, the Vascular Closure Devices Market is classified into Mechanical Closure Devices, Passive Closure Devices, and Active Closure Devices. The Vascular Closure Devices market comprises various segments, out of which Mechanical Closure Devices are dominant. These devices include physical techniques for suturing or clipping the vessels after vascular procedures to aid in hemostasis. They have gained traction in many institutions because they are dependable, simple to use, and effective in attaining the larger goal of rapid closure with little or no difficulties. Further, mechanical technologies improve patient recovery and reduce hospitalization time compared to human personnel because they are the best option for healthcare institutions. As the popularity of vascular intervention solutions employed in clinical practices grows, this segment's sales increase.

Based on the application, the Vascular Closure Devices Market is classified into Cardiology, Radiology, Interventional Procedures, Peripheral Vascular Interventions, and Others. Interventional procedures hold the largest share of the Vascular Closure Devices market. This trend is related to the increasing use of minimally invasive operations and the requirement for quick and effective closures following surgery. Interventional cardiology, in particular, can make use of these devices, adding to the patient’s speedy recovery, low rate of post-procedure complications, and optimization of the entire process. Concerns about patient safety and faster recovery times help to define this category and drive market expansion.

Regional Analysis

The North American Vascular Closure Devices (VCD) market is growing rapidly due to the rising incidence of cardiovascular diseases and enhanced use of minimally invasive procedures. The region has a well-developed healthcare organization, patient demand is quite high, and the use of novel technologies is actively encouraged. All players are focusing on new ideas and product development, and numerous VCD solutions are available to suit a wide range of clinical scenarios. Further, favorable government policies and reimbursement structures are improving market access. Because of the increasing focus of hospitals and centers for outpatients on their operations and patients’ rehabilitation, the market for VCDs will sustain its growth in the next several years.

The Asia Pacific vascular closure devices market is driven by the rising incidence of CVDs, an aging population, and increased awareness of less invasive techniques. The key players, like China, India, and Japan, are the primary drivers of market growth, fueled by improved medical facilities and technology. Further, the rise of interventional procedures and affiliations between local and global manufacturers and suppliers is improving market access. Approvals from regulatory agencies, as well as new product offers such as ecologically sensitive items and better recovery rate products, are all driving market changes. In summary, the analyzed region has the potential to attract both established leaders and new competitors in the vascular closure devices industry.

Competitive Landscape

The Vascular Closure Devices Market is highly competitive. Abbott Laboratories, Medtronic plc, and Boston Scientific Corporation are leading companies working on improved vascular closure devices. The Perclose ProGlide Suture-Mediated Closure System developed in recent years, received approvals because it helps patients recover faster. The case has shown that Medtronic has added new closure systems to its solutions, including new material for better performance. Furthermore, Teleflex and AngioDynamics are investing in research to bring innovative approaches to the market that will make operations efficient and effective. This competitive dynamic is exacerbated by the increased use of minimally invasive treatments, which need the use of next-generation vascular closure devices. Thus, recognizing that approvals and clinical exams for new products are already forthcoming, the market should further develop and introduce advanced technologies.

Vascular Closure Devices Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Free Sample Report

Recent Developments:

• In December 2023, Vivasure Medical Ltd. enrolled the first participants in the ELITE clinical investigation of the PerQseal Elite. The multicenter single-arm clinical research sought to assess the safety and efficacy of PerQseal Elite.
• In October 2023, Terumo Corporation announced that its two cutting-edge closure devices, Angio-Seal VIP and Femoseal, have achieved CE certification.
• In February 2023, Terumo Corporation bought Medeon Biodesign, Inc. to add large bore vascular closure devices to their product range and expand the interventional access device business.

Report Coverage:

By Product Type

• Mechanical Closure Devices
  • Clip-based devices
  • Suture-based devices
• Passive Closure Devices
  • Collagen-based devices
  • Gel-based devices
• Active Closure Devices
  • Balloon-assisted devices
  • Other active devices

By Application

• Cardiology
• Radiology
• Interventional Procedures
• Peripheral Vascular Interventions
• Others

By Material

• Polymer-based closure devices
• Suture-based closure devices
• Metal-based closure devices
• Collagen-based closure devices
• Others

By End-User

• Hospitals
• Ambulatory Surgical Centers (ASCs)
• Specialty Clinics
• Diagnostic Imaging Centers

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• Abbott Laboratories
• Terumo Corporation
• Medtronic plc
• Boston Scientific Corporation
• Cardinal Health, Inc.
• AngioDynamics, Inc.
• Teleflex Incorporated
• St. Jude Medical
• Johnson & Johnson
• Vascular Solutions, Inc.
• Avinger, Inc.
• Merit Medical Systems, Inc.
• Spectranetics Corporation
• C.R. Bard
• LifeTech Scientific Corporation

Frequently Asked Questions (FAQs)